Navidea Biopharmaceuticals Inc announced the US launch of Lymphoseek Injection for use in lymphatic mapping procedures performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. Lymphoseek was approved by the FDA in March 2013.
As part of Navidea’s US distribution partnership, Cardinal Health is responsible for the sale and distribution of Lymphoseek to health care professionals through its existing network of nuclear pharmacies. Lymphoseek has been priced at $300 per patient procedure.
Navidea believes these procedures are currently reimbursable under established Medicare codes and expects to apply for and receive a unique pass-through code for Lymphoseek within a few months.
